AC
VINC icon

Armistice Capital’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Armistice Capital’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-28,351
Closed -$149K – 293
2024
Q4 		$149K Sell
28,351
-106,849
-79% -$702K ﹤0.01% 197
2024
Q3 		$1.94M Buy
135,200
+35,800
+36% +$491K 0.03% 158
2024
Q2 		$1.61M Buy
+99,400
New +$2.49M 0.02% 153

Other funds holding VINC

SRC
Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Armistice Capital's VINC Position: Q1 2025 in Review

Armistice Capital sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q1 2025, closing a stake of 28,351 shares — an estimated $149K sold.

Armistice Capital first reported a position in VINC in Q2 2024 and held it in 3 quarters. The position peaked at $1.94M in Q3 2024. 14 funds tracked by Wall St. Rank hold VINC as of Q1 2025.

  • Armistice Capital reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Armistice Capital sold 28,351 Vincerx Pharma, Inc. Common Stock shares in Q1 2025, an estimated $149K.
  • Armistice Capital first reported a position in Vincerx Pharma, Inc. Common Stock in Q2 2024 and held it in 3 quarters.
  • Armistice Capital's Vincerx Pharma, Inc. Common Stock position peaked at $1.94M in Q3 2024.
  • 14 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q1 2025.

Based on Armistice Capital's 13F filing for Q1 2025, filed 15 May 2025.